Effects of DU 24565 (6-nitroquipazine) on Serotoninergic and Noradrenergic Neurones of the Rat Brain and Comparison with the Effects of Quipazine

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1984 Jun 1

PMID 6206407

Citations 15

Authors

K Classen

M Gothert

E Schlicker

Affiliations

Soon will be listed here.

Abstract

Rat brain cortex slices were prepared in order to study the influence of DU 24565 (6-nitroquipazine) and quipazine on the accumulation of tritium, and to investigate the effects of DU 24565 on the electrically evoked (3 Hz) tritium overflow from slices preincubated with 3H-serotonin (3H-5-HT) or 3H-noradrenaline (3H-NA). The influence of DU 24565 and quipazine on the activity of MAO was studied in rat brain homogenates, using labelled serotonin as a substrate. In cortex slices preincubated with either 3H-5-HT or 3H-NA, DU 24565 increased the electrically evoked 3H overflow (higher potency in slices preincubated with 3H-5-HT; the percentage of 3H accounted for by unmetabolized 3H-5-HT was also increased). The facilitatory effects of DU 24565 on evoked 3H overflow were abolished when the respective monoamine uptake mechanisms had previously been blocked by citalopram and cocaine, respectively. The inhibitory effects of unlabelled 5-HT and NA on the evoked 3H overflow from cortex slices preincubated with 3H-5-HT were not altered by DU 24565. Similarly, the drug did not affect the inhibition by NA of the evoked 3H overflow from cortex slices preincubated with 3H-NA. Quipazine was a weak and non-selective inhibitor of the accumulation of 3H-5-HT and 3H-NA. DU 24565 was about 65 times more potent and about 1100 times more selective than quipazine as an inhibitor of 3H-5-HT accumulation, and it was also superior to citalopram and paroxetine in this respect.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Serotonin and beyond-a tribute to Manfred Göthert (1939-2019).

Bonisch H, Fink K, Malinowska B, Molderings G, Schlicker E Naunyn Schmiedebergs Arch Pharmacol. 2021; 394(9):1829-1867.

PMID: 33991216 PMC: 8376721. DOI: 10.1007/s00210-021-02083-5.

Stimulation of serotonin release in the rat brain cortex by activation of ionotropic glutamate receptors and its modulation via alpha 2-heteroreceptors.

Fink K, Schmitz V, Boing C, Gothert M Naunyn Schmiedebergs Arch Pharmacol. 1995; 352(4):394-401.

PMID: 8532067 DOI: 10.1007/BF00172776.

Effects of DU 24565 (6-nitroquipazine) on serotoninergic and noradrenergic neurones of the rat brain and comparison with the effects of quipazine.

Classen K, Gothert M, Schlicker E Naunyn Schmiedebergs Arch Pharmacol. 1984; 326(3):198-202.

PMID: 6206407 DOI: 10.1007/BF00505318.

Proceedings of the British Pharmacological Society. 18th-20th December 1985. Abstracts.

Br J Pharmacol. 1986; 87 Suppl:1P-229P.

PMID: 3955310 PMC: 1916640.

Serotonin (5-HT) enhances hippocampal noradrenaline (NA) release: evidence for facilitatory 5-HT receptors within the CNS.

Feuerstein T, Hertting G Naunyn Schmiedebergs Arch Pharmacol. 1986; 333(3):191-7.

PMID: 3762733 DOI: 10.1007/BF00512929.

References

Starke K . Presynaptic receptors. Annu Rev Pharmacol Toxicol. 1981; 21:7-30. DOI: 10.1146/annurev.pa.21.040181.000255. View

Waldmeier P, Baumann P, Maitre L . CGP 6085 A, a new, specific, inhibitor of serotonin uptake: neurochemical characterization and comparison with other serotonin uptake blockers. J Pharmacol Exp Ther. 1979; 211(1):42-9. View

Hamon M, Bourgoin S, Enjalbert A, Bockaert J, Hery F, Ternaux J . The effects of quipazine on 5-HT metabolism in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1976; 294(1):99-108. DOI: 10.1007/BF00692790. View

Martin L, Sanders-Bush E . The serotonin autoreceptor: antagonism by quipazine. Neuropharmacology. 1982; 21(5):445-50. DOI: 10.1016/0028-3908(82)90029-6. View

Petersen E, Olsson S, Squires R . Effects of 5HT uptake inhibitors on the pressor response to 5HT in the pithed rat. The significance of the 5HT blocking property. Eur J Pharmacol. 1977; 43(3):209-15. DOI: 10.1016/0014-2999(77)90019-x. View

Engel G, Gothert M, Muller-Schweinitzer E, Schlicker E, Sistonen L, Stadler P . Evidence for common pharmacological properties of [3H]5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn Schmiedebergs Arch Pharmacol. 1983; 324(2):116-24. DOI: 10.1007/BF00497016. View

Frankhuyzen A, Mulder A . Pharmacological characterization of presynaptic alpha-adrenoceptors modulating [3H]noradrenaline and [3H]5-hydroxytryptamine release from slices of the hippocampus of the rat. Eur J Pharmacol. 1982; 81(1):97-106. DOI: 10.1016/0014-2999(82)90605-7. View

Baumann P, Waldmeier P . Further evidence for negative feedback control of serotonin release in the central nervous system. Naunyn Schmiedebergs Arch Pharmacol. 1981; 317(1):36-43. DOI: 10.1007/BF00506254. View

Langer S . Presynaptic regulation of the release of catecholamines. Pharmacol Rev. 1980; 32(4):337-62. View

10.

Wesemann W, Ekenna O . Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittelforschung. 1982; 32(10):1241-3. View

11.

Gothert M, Schlicker E, Kostermann F . Relationship between transmitter uptake inhibition and effects of alpha-adrenoceptor agonists on serotonin and noradrenaline release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol. 1983; 322(2):121-8. DOI: 10.1007/BF00512384. View

12.

Hyttel J . Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 1982; 6(3):277-95. DOI: 10.1016/s0278-5846(82)80179-6. View

13.

Graffe K, STEFANO F, Langer S . Preferential metabolism of (-) 3 H-norepinephrine through the deaminated glycol in the rat vas deferens. Biochem Pharmacol. 1973; 22(10):1147-60. DOI: 10.1016/0006-2952(73)90231-1. View

14.

Vaatstra W, Eigeman L . Du 24565, a quipazine derivative, a potent selective serotonin uptake inhibitor. Eur J Pharmacol. 1981; 70(2):195-202. DOI: 10.1016/0014-2999(81)90214-4. View

15.

Gothert M, Huth H, Schlicker E . Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol. 1981; 317(3):199-203. DOI: 10.1007/BF00503816. View

16.

Classen K, Gothert M, Schlicker E . Effects of DU 24565 (6-nitroquipazine) on serotoninergic and noradrenergic neurones of the rat brain and comparison with the effects of quipazine. Naunyn Schmiedebergs Arch Pharmacol. 1984; 326(3):198-202. DOI: 10.1007/BF00505318. View

17.

Steppeler A, Doring C, HEDLER L, Starke K . Effect of amezinium on the release and catabolism of 3H-monoamines in brain slices. Biochem Pharmacol. 1982; 31(14):2395-402. DOI: 10.1016/0006-2952(82)90535-4. View

18.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

19.

MCCAMAN R, McCaman M, Hunt J, Smith M . MICRODETERMINATION OF MONOAMINE OXIDASE AND 5-HYDROXYTRYPTOPHAN DECARBOXYLASE ACTIVITIES IN NERVOUS TISSUES. J Neurochem. 1965; 12:15-23. DOI: 10.1111/j.1471-4159.1965.tb10246.x. View

20.

Martin L, Sanders-Bush E . Comparison of the pharmacological characteristics of 5 HT1 and 5 HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn Schmiedebergs Arch Pharmacol. 1982; 321(3):165-70. DOI: 10.1007/BF00505480. View